샘플 요청 목록

 카트 문의
시장보고서
상품코드
1551569

세계의 원발성 경화성 담관염 치료제 시장

Primary Sclerosing Cholangitis Treatment
발행일: | 리서치사: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 페이지 정보: 영문 285 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

원발성 경화성 담관염 치료제 세계 시장 규모는 2030년까지 2억 2,010만 달러에 달할 것으로 전망

2023년 1억 8,570만 달러로 추정되는 원발성 경화성 담관염 치료제 세계 시장은 2023-2030년의 분석 기간 동안 연평균 2.5% 성장하여 2030년에는 2억 2,010만 달러에 달할 것으로 예상됩니다. 본 보고서에서 분석한 부문 중 하나인 경구 투여는 CAGR 2.8%를 기록하여 분석 기간 종료 시점에 1억 6,950만 달러에 도달할 것으로 예측됩니다. 비경구 투여 부문의 성장률은 분석 기간 동안 CAGR 1.6%로 추정됩니다.

미국 시장 5,060만 달러로 추정, 중국은 CAGR 5.0%로 성장 전망

미국의 원발성 경화성 담관염 치료 시장은 2023년 5,060만 달러로 추정됩니다. 세계 2위의 경제 대국인 중국은 2030년까지 4,390만 달러 규모에 도달할 것으로 예상되며, 분석 기간인 2023-2030년 동안 5.0%의 연평균 복합 성장률(CAGR)을 나타낼 것으로 예상됩니다. 다른 주목할 만한 지역 시장으로는 일본과 캐나다가 있으며, 분석 기간 동안 각각 0.6%와 1.8%의 연평균 복합 성장률(CAGR)을 나타낼 것으로 예상됩니다. 유럽에서는 독일이 연평균 1.2%의 성장률을 보일 것으로 예상됩니다.

세계 원발성 경화성 담관염 치료제 시장 - 주요 동향 및 촉진요인 요약

원발성 경화성 담관염이란?

원발성 경화성 담관염(PSC)은 담관의 염증과 흉터를 특징으로하는 만성 진행성 간 질환으로 간 손상 및 궁극적 인 간부전으로 이어질 수 있으며, PSC의 정확한 원인은 불분명하지만 종종자가 면역 질환과 관련이 있으며 염증성 장 질환(IBD)과 강한 상관 관계가 있습니다. 증상으로는 황달, 가려움증, 복통, 피로감 등이 있으며, 간 손상이 뚜렷해질 때까지 조용히 진행되는 경우가 많으며, PSC의 치료는 주로 증상 관리, 질병 진행 억제 및 합병증에 대처하는 데 중점을 둡니다. 간 기능을 개선하고 질병의 진행을 늦추기 위해 우르소데옥시콜산(UDCA)과 같은 약물이 일반적으로 사용되며, PSC가 간부전에 도달하면 간 이식이 결정적인 치료법으로 고려됩니다. 그러나 PSC는 복잡하고 다른 질환과의 연관성이 있기 때문에 이 질환을 관리하기 위해서는 환자 개개인의 필요에 따라 종합적이고 다학제적인 접근이 필요합니다.

원발성 경화성 담관염 치료의 최신 발전은?

최근 원발성 경화성 담관염(PSC) 치료의 발전은 새로운 치료법과 맞춤 치료 전략으로 환자 예후를 개선하는 데 초점을 맞추었습니다. 원발성 경화성 담관염의 기본 메커니즘에 대한 새로운 연구는 면역 체계를 조절하고 담관 내 염증을 억제하는 것을 목표로 하는 표적 치료제를 개발했습니다. 임상시험에서 오베티콜산과 같은 약물의 효능이 검토되고 있습니다. 오베티콜산은 PSC 환자의 간 염증과 섬유화를 억제하는 데 유망한 것으로 나타났습니다. 또한, PSC의 유전적, 분자적 기반이 밝혀지면서 개인의 유전적 프로파일과 질병 특성에 따라 보다 맞춤화된 치료 계획을 세울 수 있는 정밀의료의 길이 열리고 있습니다. 또한, 치료 효과를 높이고 복잡한 PSC 사례에 대응하기 위해 기존 약물과 새로운 약물을 결합한 병용요법의 역할도 검토되고 있습니다. 이러한 발전은 PSC를 관리하기 위한 보다 효과적이고 맞춤 치료법으로의 전환을 의미합니다.

생활습관 변화와 지지요법은 PSC 관리에 어떤 영향을 미칠까?

원발성 경화성 담관염(PSC)의 관리에는 약물 치료 외에도 생활습관 개선과 지지 요법이 중요한 역할을 합니다. 간 건강을 지원하고 증상을 관리하기 위해 흡수 장애와 영양 결핍의 위험을 줄이기 위해 저지방 식단을 포함한 식단 변경을 권장하는 경우가 많습니다. 염증성 장 질환(IBD)과 같은 관련 질환을 정기적으로 모니터링하고 관리하는 것은 전신 건강을 최적화하고 PSC와 관련된 합병증을 줄이는 데 필수적입니다. 가려움증을 억제하는 약물 치료, 비타민 보충, 골다공증 및 당뇨병과 같은 합병증 치료와 같은 지지 요법도 종합적인 치료에 필수적입니다. 환자 교육 및 심리적 지원은 PSC와 같은 만성 질환을 관리하는 데 있어 중요한 측면으로, 환자가 정서적, 신체적 문제를 극복할 수 있도록 돕습니다. 간 전문의, 소화기 전문의, 영양사 및 기타 전문가들이 협력하여 PSC를 관리하고 환자의 삶의 질을 향상시키기 위한 종합적인 접근을 할 수 있습니다.

원발성 경화성 담관염 치료 시장의 성장을 가속하는 요인은 무엇일까?

원발성 경화성 담관염(PSC) 치료 시장의 성장은 여러 가지 요인에 의해 주도되고 있습니다. PSC의 근본적인 병태생리를 해결하기 위한 새로운 치료 표적 발굴 및 신약 개발에 초점을 맞춘 연구가 진행 중이며, PSC의 유병률 증가와 의료진 사이에서 PSC에 대한 인식이 높아짐에 따라 치료 옵션 개선에 대한 수요가 증가하고 있습니다. 수요에 박차를 가하고 있습니다. 제약회사들의 임상시험 증가와 의약품 개발에 대한 투자는 PSC에 대한 더 효과적인 치료법과 더 나은 관리 전략의 필요성을 반영하고 있습니다. 또한, 의료 서비스 접근성 확대와 간 전문센터 증가는 더 많은 환자들에게 고급 치료와 다학제적 치료를 제공함으로써 시장 성장에 기여하고 있습니다. 또한, PSC 관리에 대한 개별화 접근법이 확산됨에 따라 개인 맞춤형 의료와 정밀 치료를 촉진하는 움직임도 기술 혁신과 시장 확대의 원동력이 되고 있습니다. 이러한 요인들이 복합적으로 작용하여 PSC 치료 시장은 역동적으로 성장하고 있으며, 환자의 복잡한 요구에 부응하고 간질환 분야의 발전에 기여하고 있습니다.

조사 대상 기업 예시(총 48건)

  • Acorda Therapeutics, Inc.
  • Dr. Falk Pharma GmbH
  • Durect Corporation
  • Gilead Sciences, Inc.
  • HighTide Therapeutics, Inc.
  • Immunic AG
  • Intercept Pharmaceuticals, Inc.
  • Merck & Co.
  • NGM Biopharmaceuticals Inc.
  • Novartis AG
  • Pliant Therapeutics
  • Sirnaomics, Inc.
  • akeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
  • Zydus Pharmaceuticals（USA）Inc.

목차

제1장 조사 방법

제2장 주요 요약

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트(UAE)
  • 기타 중동
  • 아프리카

제4장 경쟁

LSH 24.09.19

Global Primary Sclerosing Cholangitis Treatment Market to Reach US$220.1 Million by 2030

The global market for Primary Sclerosing Cholangitis Treatment estimated at US$185.7 Million in the year 2023, is expected to reach US$220.1 Million by 2030, growing at a CAGR of 2.5% over the analysis period 2023-2030. Oral Administration, one of the segments analyzed in the report, is expected to record a 2.8% CAGR and reach US$169.5 Million by the end of the analysis period. Growth in the Parenteral Administration segment is estimated at 1.6% CAGR over the analysis period.

The U.S. Market is Estimated at US$50.6 Million While China is Forecast to Grow at 5.0% CAGR

The Primary Sclerosing Cholangitis Treatment market in the U.S. is estimated at US$50.6 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$43.9 Million by the year 2030 trailing a CAGR of 5.0% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 0.6% and 1.8% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.2% CAGR.

Global Primary Sclerosing Cholangitis Treatment Market - Key Trends and Drivers Summarized

What Is Primary Sclerosing Cholangitis and How Is It Treated?

Primary Sclerosing Cholangitis (PSC) is a chronic, progressive liver disease characterized by inflammation and scarring of the bile ducts, which can lead to liver damage and eventual liver failure. The exact cause of PSC is unknown, but it is often associated with autoimmune disorders and has a strong correlation with inflammatory bowel disease (IBD). Symptoms of PSC can include jaundice, itching, abdominal pain, and fatigue, with the disease often progressing silently until significant liver damage occurs. Treatment for PSC primarily focuses on managing symptoms, slowing disease progression, and addressing complications. Medications such as ursodeoxycholic acid (UDCA) are commonly used to improve liver function and slow the progression of the disease. In cases where PSC leads to liver failure, a liver transplant may be considered as a definitive treatment option. However, due to the complexities of PSC and its association with other conditions, managing the disease requires a comprehensive, multidisciplinary approach tailored to the individual patient’s needs.

What Are the Latest Advances in Primary Sclerosing Cholangitis Treatment?

Recent advances in the treatment of Primary Sclerosing Cholangitis (PSC) have focused on improving patient outcomes through novel therapies and personalized treatment strategies. New research into the underlying mechanisms of PSC has led to the development of targeted therapies aimed at modulating the immune system and reducing inflammation within the bile ducts. Clinical trials are investigating the efficacy of drugs such as obeticholic acid, which has shown promise in reducing liver inflammation and fibrosis in patients with PSC. Additionally, advancements in the understanding of the genetic and molecular basis of PSC are paving the way for precision medicine approaches, allowing for more personalized treatment plans based on individual genetic profiles and disease characteristics. The role of combination therapies, integrating traditional medications with new agents, is also being explored to enhance treatment efficacy and manage complex cases of PSC. These developments represent a significant shift towards more effective and individualized treatment options for managing this challenging condition.

How Do Lifestyle Changes and Supportive Therapies Affect PSC Management?

In addition to pharmacological treatments, lifestyle modifications and supportive therapies play a crucial role in managing Primary Sclerosing Cholangitis (PSC). Dietary changes are often recommended to support liver health and manage symptoms, such as a low-fat diet to reduce the risk of malabsorption and nutrient deficiencies. Regular monitoring and management of associated conditions, such as inflammatory bowel disease (IBD), are essential for optimizing overall health and mitigating complications related to PSC. Supportive therapies, including the use of medications to manage itching, vitamin supplements, and treatments for complications like osteoporosis or diabetes, are also integral to comprehensive care. Patient education and psychological support are important aspects of managing a chronic disease like PSC, helping individuals cope with the emotional and physical challenges of the condition. Collaborative care involving hepatologists, gastroenterologists, dietitians, and other specialists ensures a holistic approach to managing PSC and improving quality of life for patients.

What Drives the Growth in the Primary Sclerosing Cholangitis Treatment Market?

The growth in the Primary Sclerosing Cholangitis (PSC) treatment market is driven by several factors. Advances in research and development are a major contributor, with ongoing studies focused on identifying new therapeutic targets and developing novel medications to address the underlying pathology of PSC. The increasing prevalence of PSC and the growing awareness of the disease among healthcare providers are fueling demand for improved treatment options. The rise in clinical trials and investment in drug development by pharmaceutical companies reflect the need for more effective therapies and better management strategies for PSC. Additionally, the expansion of healthcare access and the availability of specialized liver centers contribute to market growth by providing more patients with access to advanced treatments and multidisciplinary care. The push towards personalized medicine and precision treatments is also driving innovation and market expansion, as tailored approaches to PSC management become more prevalent. These factors collectively contribute to the dynamic growth of the PSC treatment market, addressing the complex needs of patients and advancing the field of hepatology.

Select Competitors (Total 48 Featured) -

  • Acorda Therapeutics, Inc.
  • Dr. Falk Pharma GmbH
  • Durect Corporation
  • Gilead Sciences, Inc.
  • HighTide Therapeutics, Inc.
  • Immunic AG
  • Intercept Pharmaceuticals, Inc.
  • Merck & Co., Inc.
  • NGM Biopharmaceuticals Inc.
  • Novartis AG
  • Pliant Therapeutics
  • Sirnaomics, Inc.
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
  • Zydus Pharmaceuticals (USA) Inc.;

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Primary Sclerosing Cholangitis Treatment - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Growing Patient Population and Increased Disease Awareness Spurs Demand for Effective PSC Treatments
    • Advancements in Pharmacological Treatments Expands Addressable Market Opportunity for Primary Sclerosing Cholangitis Therapy
    • Integration of Novel Biologics and Targeted Therapies Drives Adoption of Innovative Treatment Options
    • Focus on Early Diagnosis and Personalized Medicine Generates Demand for Tailored PSC Treatment Strategies
    • Combination Therapies and Multimodal Approaches Strengthen Business Case for Comprehensive Treatment Solutions
    • Advancements in Monitoring and Diagnostics Enhance Treatment Outcomes
    • Growing Interest in Patient-Centric Care and Support Programs Generates New Market Opportunities for PSC Therapies
    • Expansion of Healthcare Access and Specialized Clinics in Emerging Markets Drives Demand for PSC Treatments
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Primary Sclerosing Cholangitis Treatment Market Analysis of Annual Sales in US$ for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Primary Sclerosing Cholangitis Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2023 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Primary Sclerosing Cholangitis Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 4: World 16-Year Perspective for Primary Sclerosing Cholangitis Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Oral Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2023 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Oral Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 7: World 16-Year Perspective for Oral Administration by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Parenteral Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2023 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Parenteral Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 10: World 16-Year Perspective for Parenteral Administration by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Other Administration Routes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2023 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Other Administration Routes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 13: World 16-Year Perspective for Other Administration Routes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2023 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 16: World 16-Year Perspective for Hospital Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2023 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 19: World 16-Year Perspective for Retail Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Online Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2023 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Online Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 22: World 16-Year Perspective for Online Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Primary Sclerosing Cholangitis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 23: USA Recent Past, Current & Future Analysis for Primary Sclerosing Cholangitis Treatment by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 24: USA Historic Review for Primary Sclerosing Cholangitis Treatment by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 25: USA 16-Year Perspective for Primary Sclerosing Cholangitis Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Parenteral Administration and Other Administration Routes for the Years 2014, 2024 & 2030
    • TABLE 26: USA Recent Past, Current & Future Analysis for Primary Sclerosing Cholangitis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 27: USA Historic Review for Primary Sclerosing Cholangitis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 28: USA 16-Year Perspective for Primary Sclerosing Cholangitis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 29: Canada Recent Past, Current & Future Analysis for Primary Sclerosing Cholangitis Treatment by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 30: Canada Historic Review for Primary Sclerosing Cholangitis Treatment by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 31: Canada 16-Year Perspective for Primary Sclerosing Cholangitis Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Parenteral Administration and Other Administration Routes for the Years 2014, 2024 & 2030
    • TABLE 32: Canada Recent Past, Current & Future Analysis for Primary Sclerosing Cholangitis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 33: Canada Historic Review for Primary Sclerosing Cholangitis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 34: Canada 16-Year Perspective for Primary Sclerosing Cholangitis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • JAPAN
    • Primary Sclerosing Cholangitis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 35: Japan Recent Past, Current & Future Analysis for Primary Sclerosing Cholangitis Treatment by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 36: Japan Historic Review for Primary Sclerosing Cholangitis Treatment by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 37: Japan 16-Year Perspective for Primary Sclerosing Cholangitis Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Parenteral Administration and Other Administration Routes for the Years 2014, 2024 & 2030
    • TABLE 38: Japan Recent Past, Current & Future Analysis for Primary Sclerosing Cholangitis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 39: Japan Historic Review for Primary Sclerosing Cholangitis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 40: Japan 16-Year Perspective for Primary Sclerosing Cholangitis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • CHINA
    • Primary Sclerosing Cholangitis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 41: China Recent Past, Current & Future Analysis for Primary Sclerosing Cholangitis Treatment by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 42: China Historic Review for Primary Sclerosing Cholangitis Treatment by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 43: China 16-Year Perspective for Primary Sclerosing Cholangitis Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Parenteral Administration and Other Administration Routes for the Years 2014, 2024 & 2030
    • TABLE 44: China Recent Past, Current & Future Analysis for Primary Sclerosing Cholangitis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 45: China Historic Review for Primary Sclerosing Cholangitis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 46: China 16-Year Perspective for Primary Sclerosing Cholangitis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • EUROPE
    • Primary Sclerosing Cholangitis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 47: Europe Recent Past, Current & Future Analysis for Primary Sclerosing Cholangitis Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ for Years 2023 through 2030 and % CAGR
    • TABLE 48: Europe Historic Review for Primary Sclerosing Cholangitis Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 49: Europe 16-Year Perspective for Primary Sclerosing Cholangitis Treatment by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
    • TABLE 50: Europe Recent Past, Current & Future Analysis for Primary Sclerosing Cholangitis Treatment by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 51: Europe Historic Review for Primary Sclerosing Cholangitis Treatment by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 52: Europe 16-Year Perspective for Primary Sclerosing Cholangitis Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Parenteral Administration and Other Administration Routes for the Years 2014, 2024 & 2030
    • TABLE 53: Europe Recent Past, Current & Future Analysis for Primary Sclerosing Cholangitis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 54: Europe Historic Review for Primary Sclerosing Cholangitis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 55: Europe 16-Year Perspective for Primary Sclerosing Cholangitis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • FRANCE
    • Primary Sclerosing Cholangitis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 56: France Recent Past, Current & Future Analysis for Primary Sclerosing Cholangitis Treatment by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 57: France Historic Review for Primary Sclerosing Cholangitis Treatment by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 58: France 16-Year Perspective for Primary Sclerosing Cholangitis Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Parenteral Administration and Other Administration Routes for the Years 2014, 2024 & 2030
    • TABLE 59: France Recent Past, Current & Future Analysis for Primary Sclerosing Cholangitis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 60: France Historic Review for Primary Sclerosing Cholangitis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 61: France 16-Year Perspective for Primary Sclerosing Cholangitis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • GERMANY
    • Primary Sclerosing Cholangitis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 62: Germany Recent Past, Current & Future Analysis for Primary Sclerosing Cholangitis Treatment by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 63: Germany Historic Review for Primary Sclerosing Cholangitis Treatment by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 64: Germany 16-Year Perspective for Primary Sclerosing Cholangitis Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Parenteral Administration and Other Administration Routes for the Years 2014, 2024 & 2030
    • TABLE 65: Germany Recent Past, Current & Future Analysis for Primary Sclerosing Cholangitis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 66: Germany Historic Review for Primary Sclerosing Cholangitis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 67: Germany 16-Year Perspective for Primary Sclerosing Cholangitis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 68: Italy Recent Past, Current & Future Analysis for Primary Sclerosing Cholangitis Treatment by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 69: Italy Historic Review for Primary Sclerosing Cholangitis Treatment by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 70: Italy 16-Year Perspective for Primary Sclerosing Cholangitis Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Parenteral Administration and Other Administration Routes for the Years 2014, 2024 & 2030
    • TABLE 71: Italy Recent Past, Current & Future Analysis for Primary Sclerosing Cholangitis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 72: Italy Historic Review for Primary Sclerosing Cholangitis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 73: Italy 16-Year Perspective for Primary Sclerosing Cholangitis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • Primary Sclerosing Cholangitis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 74: UK Recent Past, Current & Future Analysis for Primary Sclerosing Cholangitis Treatment by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 75: UK Historic Review for Primary Sclerosing Cholangitis Treatment by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 76: UK 16-Year Perspective for Primary Sclerosing Cholangitis Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Parenteral Administration and Other Administration Routes for the Years 2014, 2024 & 2030
    • TABLE 77: UK Recent Past, Current & Future Analysis for Primary Sclerosing Cholangitis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 78: UK Historic Review for Primary Sclerosing Cholangitis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 79: UK 16-Year Perspective for Primary Sclerosing Cholangitis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • SPAIN
    • TABLE 80: Spain Recent Past, Current & Future Analysis for Primary Sclerosing Cholangitis Treatment by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 81: Spain Historic Review for Primary Sclerosing Cholangitis Treatment by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 82: Spain 16-Year Perspective for Primary Sclerosing Cholangitis Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Parenteral Administration and Other Administration Routes for the Years 2014, 2024 & 2030
    • TABLE 83: Spain Recent Past, Current & Future Analysis for Primary Sclerosing Cholangitis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 84: Spain Historic Review for Primary Sclerosing Cholangitis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 85: Spain 16-Year Perspective for Primary Sclerosing Cholangitis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • RUSSIA
    • TABLE 86: Russia Recent Past, Current & Future Analysis for Primary Sclerosing Cholangitis Treatment by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 87: Russia Historic Review for Primary Sclerosing Cholangitis Treatment by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 88: Russia 16-Year Perspective for Primary Sclerosing Cholangitis Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Parenteral Administration and Other Administration Routes for the Years 2014, 2024 & 2030
    • TABLE 89: Russia Recent Past, Current & Future Analysis for Primary Sclerosing Cholangitis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 90: Russia Historic Review for Primary Sclerosing Cholangitis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 91: Russia 16-Year Perspective for Primary Sclerosing Cholangitis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 92: Rest of Europe Recent Past, Current & Future Analysis for Primary Sclerosing Cholangitis Treatment by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 93: Rest of Europe Historic Review for Primary Sclerosing Cholangitis Treatment by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 94: Rest of Europe 16-Year Perspective for Primary Sclerosing Cholangitis Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Parenteral Administration and Other Administration Routes for the Years 2014, 2024 & 2030
    • TABLE 95: Rest of Europe Recent Past, Current & Future Analysis for Primary Sclerosing Cholangitis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 96: Rest of Europe Historic Review for Primary Sclerosing Cholangitis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 97: Rest of Europe 16-Year Perspective for Primary Sclerosing Cholangitis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • Primary Sclerosing Cholangitis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 98: Asia-Pacific Recent Past, Current & Future Analysis for Primary Sclerosing Cholangitis Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ for Years 2023 through 2030 and % CAGR
    • TABLE 99: Asia-Pacific Historic Review for Primary Sclerosing Cholangitis Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 100: Asia-Pacific 16-Year Perspective for Primary Sclerosing Cholangitis Treatment by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
    • TABLE 101: Asia-Pacific Recent Past, Current & Future Analysis for Primary Sclerosing Cholangitis Treatment by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 102: Asia-Pacific Historic Review for Primary Sclerosing Cholangitis Treatment by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 103: Asia-Pacific 16-Year Perspective for Primary Sclerosing Cholangitis Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Parenteral Administration and Other Administration Routes for the Years 2014, 2024 & 2030
    • TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for Primary Sclerosing Cholangitis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 105: Asia-Pacific Historic Review for Primary Sclerosing Cholangitis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 106: Asia-Pacific 16-Year Perspective for Primary Sclerosing Cholangitis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • AUSTRALIA
    • Primary Sclerosing Cholangitis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
    • TABLE 107: Australia Recent Past, Current & Future Analysis for Primary Sclerosing Cholangitis Treatment by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 108: Australia Historic Review for Primary Sclerosing Cholangitis Treatment by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 109: Australia 16-Year Perspective for Primary Sclerosing Cholangitis Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Parenteral Administration and Other Administration Routes for the Years 2014, 2024 & 2030
    • TABLE 110: Australia Recent Past, Current & Future Analysis for Primary Sclerosing Cholangitis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 111: Australia Historic Review for Primary Sclerosing Cholangitis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 112: Australia 16-Year Perspective for Primary Sclerosing Cholangitis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • INDIA
    • Primary Sclerosing Cholangitis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
    • TABLE 113: India Recent Past, Current & Future Analysis for Primary Sclerosing Cholangitis Treatment by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 114: India Historic Review for Primary Sclerosing Cholangitis Treatment by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 115: India 16-Year Perspective for Primary Sclerosing Cholangitis Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Parenteral Administration and Other Administration Routes for the Years 2014, 2024 & 2030
    • TABLE 116: India Recent Past, Current & Future Analysis for Primary Sclerosing Cholangitis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 117: India Historic Review for Primary Sclerosing Cholangitis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 118: India 16-Year Perspective for Primary Sclerosing Cholangitis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • SOUTH KOREA
    • TABLE 119: South Korea Recent Past, Current & Future Analysis for Primary Sclerosing Cholangitis Treatment by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 120: South Korea Historic Review for Primary Sclerosing Cholangitis Treatment by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 121: South Korea 16-Year Perspective for Primary Sclerosing Cholangitis Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Parenteral Administration and Other Administration Routes for the Years 2014, 2024 & 2030
    • TABLE 122: South Korea Recent Past, Current & Future Analysis for Primary Sclerosing Cholangitis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 123: South Korea Historic Review for Primary Sclerosing Cholangitis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 124: South Korea 16-Year Perspective for Primary Sclerosing Cholangitis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 125: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Primary Sclerosing Cholangitis Treatment by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 126: Rest of Asia-Pacific Historic Review for Primary Sclerosing Cholangitis Treatment by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 127: Rest of Asia-Pacific 16-Year Perspective for Primary Sclerosing Cholangitis Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Parenteral Administration and Other Administration Routes for the Years 2014, 2024 & 2030
    • TABLE 128: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Primary Sclerosing Cholangitis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 129: Rest of Asia-Pacific Historic Review for Primary Sclerosing Cholangitis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 130: Rest of Asia-Pacific 16-Year Perspective for Primary Sclerosing Cholangitis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • LATIN AMERICA
    • Primary Sclerosing Cholangitis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
    • TABLE 131: Latin America Recent Past, Current & Future Analysis for Primary Sclerosing Cholangitis Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ for Years 2023 through 2030 and % CAGR
    • TABLE 132: Latin America Historic Review for Primary Sclerosing Cholangitis Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 133: Latin America 16-Year Perspective for Primary Sclerosing Cholangitis Treatment by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
    • TABLE 134: Latin America Recent Past, Current & Future Analysis for Primary Sclerosing Cholangitis Treatment by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 135: Latin America Historic Review for Primary Sclerosing Cholangitis Treatment by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 136: Latin America 16-Year Perspective for Primary Sclerosing Cholangitis Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Parenteral Administration and Other Administration Routes for the Years 2014, 2024 & 2030
    • TABLE 137: Latin America Recent Past, Current & Future Analysis for Primary Sclerosing Cholangitis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 138: Latin America Historic Review for Primary Sclerosing Cholangitis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 139: Latin America 16-Year Perspective for Primary Sclerosing Cholangitis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • ARGENTINA
    • TABLE 140: Argentina Recent Past, Current & Future Analysis for Primary Sclerosing Cholangitis Treatment by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 141: Argentina Historic Review for Primary Sclerosing Cholangitis Treatment by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 142: Argentina 16-Year Perspective for Primary Sclerosing Cholangitis Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Parenteral Administration and Other Administration Routes for the Years 2014, 2024 & 2030
    • TABLE 143: Argentina Recent Past, Current & Future Analysis for Primary Sclerosing Cholangitis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 144: Argentina Historic Review for Primary Sclerosing Cholangitis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 145: Argentina 16-Year Perspective for Primary Sclerosing Cholangitis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • BRAZIL
    • TABLE 146: Brazil Recent Past, Current & Future Analysis for Primary Sclerosing Cholangitis Treatment by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 147: Brazil Historic Review for Primary Sclerosing Cholangitis Treatment by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 148: Brazil 16-Year Perspective for Primary Sclerosing Cholangitis Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Parenteral Administration and Other Administration Routes for the Years 2014, 2024 & 2030
    • TABLE 149: Brazil Recent Past, Current & Future Analysis for Primary Sclerosing Cholangitis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 150: Brazil Historic Review for Primary Sclerosing Cholangitis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 151: Brazil 16-Year Perspective for Primary Sclerosing Cholangitis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • MEXICO
    • TABLE 152: Mexico Recent Past, Current & Future Analysis for Primary Sclerosing Cholangitis Treatment by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 153: Mexico Historic Review for Primary Sclerosing Cholangitis Treatment by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 154: Mexico 16-Year Perspective for Primary Sclerosing Cholangitis Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Parenteral Administration and Other Administration Routes for the Years 2014, 2024 & 2030
    • TABLE 155: Mexico Recent Past, Current & Future Analysis for Primary Sclerosing Cholangitis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 156: Mexico Historic Review for Primary Sclerosing Cholangitis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 157: Mexico 16-Year Perspective for Primary Sclerosing Cholangitis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • REST OF LATIN AMERICA
    • TABLE 158: Rest of Latin America Recent Past, Current & Future Analysis for Primary Sclerosing Cholangitis Treatment by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 159: Rest of Latin America Historic Review for Primary Sclerosing Cholangitis Treatment by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 160: Rest of Latin America 16-Year Perspective for Primary Sclerosing Cholangitis Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Parenteral Administration and Other Administration Routes for the Years 2014, 2024 & 2030
    • TABLE 161: Rest of Latin America Recent Past, Current & Future Analysis for Primary Sclerosing Cholangitis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 162: Rest of Latin America Historic Review for Primary Sclerosing Cholangitis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 163: Rest of Latin America 16-Year Perspective for Primary Sclerosing Cholangitis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • MIDDLE EAST
    • Primary Sclerosing Cholangitis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
    • TABLE 164: Middle East Recent Past, Current & Future Analysis for Primary Sclerosing Cholangitis Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ for Years 2023 through 2030 and % CAGR
    • TABLE 165: Middle East Historic Review for Primary Sclerosing Cholangitis Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 166: Middle East 16-Year Perspective for Primary Sclerosing Cholangitis Treatment by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
    • TABLE 167: Middle East Recent Past, Current & Future Analysis for Primary Sclerosing Cholangitis Treatment by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 168: Middle East Historic Review for Primary Sclerosing Cholangitis Treatment by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 169: Middle East 16-Year Perspective for Primary Sclerosing Cholangitis Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Parenteral Administration and Other Administration Routes for the Years 2014, 2024 & 2030
    • TABLE 170: Middle East Recent Past, Current & Future Analysis for Primary Sclerosing Cholangitis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 171: Middle East Historic Review for Primary Sclerosing Cholangitis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 172: Middle East 16-Year Perspective for Primary Sclerosing Cholangitis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • IRAN
    • TABLE 173: Iran Recent Past, Current & Future Analysis for Primary Sclerosing Cholangitis Treatment by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 174: Iran Historic Review for Primary Sclerosing Cholangitis Treatment by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 175: Iran 16-Year Perspective for Primary Sclerosing Cholangitis Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Parenteral Administration and Other Administration Routes for the Years 2014, 2024 & 2030
    • TABLE 176: Iran Recent Past, Current & Future Analysis for Primary Sclerosing Cholangitis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 177: Iran Historic Review for Primary Sclerosing Cholangitis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 178: Iran 16-Year Perspective for Primary Sclerosing Cholangitis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • ISRAEL
    • TABLE 179: Israel Recent Past, Current & Future Analysis for Primary Sclerosing Cholangitis Treatment by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 180: Israel Historic Review for Primary Sclerosing Cholangitis Treatment by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 181: Israel 16-Year Perspective for Primary Sclerosing Cholangitis Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Parenteral Administration and Other Administration Routes for the Years 2014, 2024 & 2030
    • TABLE 182: Israel Recent Past, Current & Future Analysis for Primary Sclerosing Cholangitis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 183: Israel Historic Review for Primary Sclerosing Cholangitis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 184: Israel 16-Year Perspective for Primary Sclerosing Cholangitis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • SAUDI ARABIA
    • TABLE 185: Saudi Arabia Recent Past, Current & Future Analysis for Primary Sclerosing Cholangitis Treatment by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 186: Saudi Arabia Historic Review for Primary Sclerosing Cholangitis Treatment by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 187: Saudi Arabia 16-Year Perspective for Primary Sclerosing Cholangitis Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Parenteral Administration and Other Administration Routes for the Years 2014, 2024 & 2030
    • TABLE 188: Saudi Arabia Recent Past, Current & Future Analysis for Primary Sclerosing Cholangitis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 189: Saudi Arabia Historic Review for Primary Sclerosing Cholangitis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 190: Saudi Arabia 16-Year Perspective for Primary Sclerosing Cholangitis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 191: UAE Recent Past, Current & Future Analysis for Primary Sclerosing Cholangitis Treatment by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 192: UAE Historic Review for Primary Sclerosing Cholangitis Treatment by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 193: UAE 16-Year Perspective for Primary Sclerosing Cholangitis Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Parenteral Administration and Other Administration Routes for the Years 2014, 2024 & 2030
    • TABLE 194: UAE Recent Past, Current & Future Analysis for Primary Sclerosing Cholangitis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 195: UAE Historic Review for Primary Sclerosing Cholangitis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 196: UAE 16-Year Perspective for Primary Sclerosing Cholangitis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • REST OF MIDDLE EAST
    • TABLE 197: Rest of Middle East Recent Past, Current & Future Analysis for Primary Sclerosing Cholangitis Treatment by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 198: Rest of Middle East Historic Review for Primary Sclerosing Cholangitis Treatment by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 199: Rest of Middle East 16-Year Perspective for Primary Sclerosing Cholangitis Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Parenteral Administration and Other Administration Routes for the Years 2014, 2024 & 2030
    • TABLE 200: Rest of Middle East Recent Past, Current & Future Analysis for Primary Sclerosing Cholangitis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 201: Rest of Middle East Historic Review for Primary Sclerosing Cholangitis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 202: Rest of Middle East 16-Year Perspective for Primary Sclerosing Cholangitis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • AFRICA
    • Primary Sclerosing Cholangitis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
    • TABLE 203: Africa Recent Past, Current & Future Analysis for Primary Sclerosing Cholangitis Treatment by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 204: Africa Historic Review for Primary Sclerosing Cholangitis Treatment by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 205: Africa 16-Year Perspective for Primary Sclerosing Cholangitis Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Parenteral Administration and Other Administration Routes for the Years 2014, 2024 & 2030
    • TABLE 206: Africa Recent Past, Current & Future Analysis for Primary Sclerosing Cholangitis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 207: Africa Historic Review for Primary Sclerosing Cholangitis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 208: Africa 16-Year Perspective for Primary Sclerosing Cholangitis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제